Structure Therapeutics Statistics
Total Valuation
GPCR has a market cap or net worth of $1.36 billion. The enterprise value is $449.90 million.
Important Dates
The next estimated earnings date is Friday, March 7, 2025, before market open.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GPCR has 57.26 million shares outstanding. The number of shares has increased by 91.97% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 57.26M |
| Shares Change (YoY) | +91.97% |
| Shares Change (QoQ) | +15.78% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 109.10% |
| Float | 51.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.63, with a Debt / Equity ratio of 0.00.
| Current Ratio | 27.63 |
| Quick Ratio | 27.38 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.29% and return on invested capital (ROIC) is -16.18%.
| Return on Equity (ROE) | -20.29% |
| Return on Assets (ROA) | -15.46% |
| Return on Invested Capital (ROIC) | -16.18% |
| Return on Capital Employed (ROCE) | -15.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.19M |
| Employee Count | 93 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -138,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.20% in the last 52 weeks. The beta is -2.91, so GPCR's price volatility has been lower than the market average.
| Beta (5Y) | -2.91 |
| 52-Week Price Change | -45.20% |
| 50-Day Moving Average | 28.03 |
| 200-Day Moving Average | 36.38 |
| Relative Strength Index (RSI) | 37.90 |
| Average Volume (20 Days) | 752,254 |
Short Selling Information
| Short Interest | 7.85M |
| Short Previous Month | 9.86M |
| Short % of Shares Out | 13.72% |
| Short % of Float | 15.34% |
| Short Ratio (days to cover) | 9.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.16M |
| Pretax Income | -100.26M |
| Net Income | -110.55M |
| EBITDA | -141.34M |
| EBIT | -142.16M |
| Earnings Per Share (EPS) | -$2.22 |
Full Income StatementBalance Sheet
The company has $915.29 million in cash and $4.39 million in debt, giving a net cash position of $910.90 million or $15.91 per share.
| Cash & Cash Equivalents | 915.29M |
| Total Debt | 4.39M |
| Net Cash | 910.90M |
| Net Cash Per Share | $15.91 |
| Equity (Book Value) | 896.80M |
| Book Value Per Share | 15.66 |
| Working Capital | 890.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$101.90 million and capital expenditures -$2.43 million, giving a free cash flow of -$104.33 million.
| Operating Cash Flow | -101.90M |
| Capital Expenditures | -2.43M |
| Free Cash Flow | -104.33M |
| FCF Per Share | -$1.82 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |